Bristol-Myers Squibb Commits to Global Impact Partnership and Site Advocacy Group
Ellicott City, M.D., June 10, 2015 – The Society for Clinical Research Sites (SCRS), the global trade organization fully dedicated to representing the interests of clinical research sites, today announced a two-year partnership with Bristol-Myers Squibb, a leading global biopharmaceutical company. Bristol-Myers Squibb will participate as a Global Impact Partner (GIP), a relationship indicative of Bristol-Myers Squibb’s dedication to promoting greater site sustainability across the global clinical research landscape. Bristol-Myers Squibb will also host a Site Advocacy Group.
“Bristol-Myers Squibb’s partnership with SCRS illustrates their commitment to encouraging collaboration and dialogue amongst industry stakeholders,” comments Christine Pierre, SCRS President. “SCRS is proud to welcome Bristol-Myers Squibb to our community, and applauds their desire to actively listen to the sites’ voice through their partnership and Site Advocacy Group.”
“As a company dedicated to discovering, developing and delivering innovative medicines that help patients prevail over serious diseases, we recognize the critical role clinical research sites play as collaborators in fulfilling this mission,” said Paul Biondi, senior vice president of R&D Operations, Bristol-Myers Squibb. “We look forward to partnering with SCRS as an organization representing the collective voice of clinical research sites from across the world.”
As a GIP, Bristol-Myers Squibb will participate on the SCRS Global Impact Board at an executive level, and work closely with SCRS’ Leadership Council in the development and execution of strategic initiatives for SCRS.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
Funding Cuts Threaten Diversity in Clinical Research
June 27th 2025In this video interview, Kyle McAllister, co-founder, CEO, Trially, discusses how recent federal funding cuts are likely to undermine research focused on underrepresented populations, and why long-term investment in community-based studies is essential to closing persistent health equity gaps.
Pfizer Reports Strong Phase III Results for Hympavzi in Hemophilia Patients with Inhibitors
June 26th 2025The Phase III BASIS trial found that once-weekly subcutaneous Hympavzi reduced treated bleed rates by 93% in patients with hemophilia A or B with inhibitors, offering a promising new prophylactic option for a population with limited therapeutic choices.
